Last checked at 
13 Jul 2020 07:00
13 july 2020
BioPharma Credit plc
(the "Company")
share buy-back programme
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is amending its disclosure policy to include on a regulatory information services (RIS) details of its share buyback powers which it renews annually. It is expected similar announcements will be made every time the share buyback authority is renewed.
The Company announces that it has authority to repurchase a maximum of up to 205,952,416 Shares of US$0.01 of its ordinary shares (being it outstanding shareholder authority). Such authority lasts until the next shareholder authority granted, or where expressly revoked by shareholders. The buyback may be funded from the Company's resources (including redemptions on funds the Company has invested in and debt facilities). No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buy-back which would equate to a premium on the net asset value.
The Company has appointed J.P. Morgan Securities plc to act as its broker in respect of the buy- back.
The buy-back will be undertaken pursuant the Company's discount management programme.
This arrangement is in accordance with Chapter 12 of the FCA Listing Rules and the Company's general authority to repurchase shares.
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509
J.P. Morgan Cazenove
+44 (0)20 7742 4000
William Simmonds
Oliver Kenyon
Buchanan
+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24